Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
Treatments Autoimmune/autoinflammatory
Author: Niranthari Chinniah MBBS, Dermatology Registrar, Sydney, Australia; Dr.Monisha Gupta, MD, FACD, Dermatologist, Sydney, Australia; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, July 2014.
Introduction
How it works
Different types
Grafting of melanocyte-rich tissue
Grafting of melanocyte cell suspensions
Contraindications and cautions
Vitiligo is a chronic skin disorder that causes areas of skin to lose colour. It presents as depigmented (white) patches. Exposed body sites, such as the face, elbows, knees, hands and feet, are often involved, resulting in significant cosmetic concerns. Vitiligo is usually treated with creams and tablets, or by phototherapy. Vitiligo may fail to improve or clear with these treatments.
Surgical treatment options can be considered in patients with stable vitiligo.
The goal of vitiligo surgery is to achieve complete repigmentation that cosmetically matches the surrounding normal skin.
Appropriate patient selection is vital in ensuring the best outcome, as not all patients or vitiliginous skin sites are suitable for surgery. Prior to surgery the following patient factors should be considered:
All types of surgical treatment aim to transfer melanocytes (pigment-producing cells) from normal skin (the donor site) to the skin affected by vitiligo.
Surgical treatment for vitiligo can be considered in two main categories:
Commonly used surgical techniques for repigmentation surgery are listed below
Types of vitiligo surgery |
|
---|---|
Grafting of melanocyte-rich tissue |
Grafting of melanocyte cell suspensions |
|
|
The superficial or uppermost layer of affected skin is usually removed under local anaesthesia in an outpatient setting. Techniques to remove the skin include:
Miniature punch grafting is one of the most commonly used techniques, due to its simplicity and efficacy. Bits of skin about 2 mm in diameter are punched out from the donor site on buttock or thigh and placed on the donor site of vitiliginous skin, where recipient chambers have also been created by punches.
Potential immediate complications of miniature punch grafting include:
Mid- to long-term complications of miniature punch grafting include:
Recipient site, back of hand (a). Two-mm diameter full-thickness skin grafts are removed from a pigmented donor area on the thigh (b), using a punch (c). At the same time, equal sizes of holes are made in the white-skinned recipient area (d). The punched out pieces of skin from the donor area are then transplanted into the recipient area (e). About 30 grafts can be easily inserted at one sitting. The process may be repeated to treat larger areas. Outcome (f). Courtesy of Dr M.Gupta, Sydney, Australia.
In suction blister grafting, negative pressure is applied to the normally pigmented donor site to promote the formation of multiple blisters.
Blisters may be raised using one of the following options:
The bases of syringes of sizes 10 ml and 20 ml are coated with vaseline and are applied on the donor site. It usually takes 1.5 to 2.5 hours for the development of blisters. The roofs of the blisters (the grafts) are surgically removed, cut to the appropriate size and shape, and transplanted onto the prepared recipient site.
Good cosmetic results can be achieved, with minimal scarring of the donor site or cobblestoning at the recipient site. Suction blister grafting is generally safe, easy to perform and inexpensive, with good success rates. However, it can also be very time consuming, and can be performed only on small areas of skin.
Complications of suction blister grafting are limited to:
Split thickness skin grafting involves shaving off thin layers of skin from the donor site. In comparison to punch grafting and suction blister grafting, split thickness skin grafting can cover larger areas and produces uniform pigmentation with no cobblestoning.
Complications of split thickness skin grafting include:
Autologous non-cultured epidermal cell suspensions are gaining popularity around the world as the treatment of choice for surgical management of vitiligo. Pre-prepared kits are available.
Tissue is harvested from a donor site and is incubated with trypsin to separate the epidermis from the dermis. The melanocytes are then separated from the epidermis and made into a cell suspension that can then be transplanted onto the de-epithelialized recipient skin.
Autologous non-cultured epidermal cell suspensions allow large areas to be treated in one session using a small donor graft. They result in excellent colour matching. However the procedure is expensive and complex. Due to stringent rules regarding tissue handling in Australia and elsewhere, it is not yet widely available.
With cultured melanocyte suspensions, tissue is also harvested and incubated with trypsin. However, after separation of the epidermis, the melanocytes and keratinocytes are incubated in a medium containing growth factors. The cultured suspension is then transplanted on to de-epithelialized recipient skin.
Cultured melanocyte suspensions allow a large area to be treated in a single session. It uses a larger donor-to-recipient ratio than the non-cultured technique. This sophisticated technique requires a special laboratory.
Vitiligo surgery is used in stable disease, ie vitiligo that does not progress over a period of 6–12 months. Segmental vitiligo generally has better surgical outcomes than non-segmental vitiligo. Outcome also depends on body site, with surgical treatment of genitals, lips, eyelids and bony prominences particularly variable.
Because the progress of the disease can be difficult to predict, vitiligo surgery is contraindicated in: